ArticleDiscover oncology2025
Prognostic related signature predicts the benefits of immunotherapy for kidney renal clear cell carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and validation of a plasma-urine metabolism diagnostic model for renal cell carcinoma using machine learning.World journal of urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) stands as the pivotal pathological subtype of renal cell carcinoma. However, there exists a dearth of pertinent biological targets crucial for advancing the clinical application of ccRCC. In our investigation, we employed the weighted gene co-expression network analysis (WGCNA) to discern 13 distinct gene co-expression modules, with the yellow module exhibiting a pronounced association with tumorigenesis. Concurrently, we scrutinized 6147 differentially expressed genes through rigorous differential expression analysis. Through an intersecting approach with the genes within the yellow module, we pinpointed 265 cancer-related genes displaying notable differential expression. Subsequent Cox-regression analysis unveiled that among the 265 genes, four were notably linked to ccRCC prognosis. Furthermore, we executed single-sample gene set enrichment analysis (ssGSEA) on the signature comprising these four genes, subsequently deriving normalized enrichment scores (NESs). This investigation substantiated that the said signature bears significant implications for prognosis, holding the potential to forecast the efficacy of immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.